The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

被引：3
作者：
Isidori, Alessandro [1 ]
Merli, Francesco [2 ]
Angrilli, Francesco [3 ]
Ferrara, Felicetto [4 ]
Alesiani, Francesco [5 ]
Visani, Giuseppe [1 ]
机构：
[1] San Salvatore Hosp, Hematol & Hematopoiet Stem Cell Transplant Ctr, I-61100 Pesaro, Italy
[2] Arcispedale, Dept Oncohematol, Reggio Emilia, Italy
[3] Santo Spirito Hosp, Dept Hematol, Pescara, Italy
[4] Cardarelli Hosp, Dept Hematol, Naples, Italy
[5] Bartolomeo Eustacchio Hosp, Dept Oncohematol, San Severino Marc, Italy
来源：
LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 01期
关键词：
D O I：
10.3109/10428194.2010.525726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：148 / 149
页数：2
相关论文
共 9 条
  • [1] Brusamolino E, 2006, HAEMATOLOGICA, V91, P496
  • [2] INFECTIOUS AND IMMUNOSUPPRESSIVE COMPLICATIONS OF PURINE ANALOG THERAPY
    CHESON, BD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) : 2431 - 2448
  • [3] High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone
    Kamel, Sarah
    O'Connor, Shaun
    Lee, Newton
    Filshie, Robin
    Nandurkar, Harshal
    Tam, Constantine S.
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 797 - 801
  • [4] Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma
    Katsuya, Hiroo
    Suzumiya, Junji
    Sasaki, Hidenori
    Ishitsuka, Kenji
    Shibata, Takao
    Takamatsu, Yasushi
    Tamura, Kazuo
    [J]. LEUKEMIA & LYMPHOMA, 2009, 50 (11) : 1818 - 1823
  • [5] Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
    Kolstad, Arne
    Holte, Harald
    Fossa, Alexander
    Lauritzsen, Grete Fossum
    Gaustad, Peter
    Torfoss, Dag
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 139 - 140
  • [6] Morrison V A, 2001, Expert Rev Anticancer Ther, V1, P84, DOI 10.1586/14737140.1.1.84
  • [7] Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
    Pfreundschuh, M
    Trümper, L
    Kloess, M
    Schmits, R
    Feller, AC
    Rübe, C
    Rudolph, C
    Reiser, M
    Hossfeld, DK
    Eimermacher, H
    Hasenclever, D
    Schmitz, N
    Loeffler, M
    [J]. BLOOD, 2004, 104 (03) : 634 - 641
  • [8] A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
    Tadmor, Tamar
    McLaughlin, Peter
    Polliack, Aaron
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 737 - 738
  • [9] Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma
    Venhuizen, Annemarie C.
    Hustinx, Willem N. M.
    van Houte, Arend-Jan
    Veth, Gerda
    van der Griend, Rene
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (03) : 275 - 276
1